Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
Subscribe To Our Newsletter & Stay Updated
